SCHEMBL3339475

SCHEMBL3339475

O=C(O)CCc1cc(Cl)c(-c2noc(-c3cn4cc(C(F)(F)F)cc(Br)c4n3)n2)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.37
S1PR1 P21453 13/20 0.36
NPC1 O15118 2/20 0.36
NFKB1 P19838 2/20 0.36
RAB9A P51151 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
S1PR5 Q9H228 3/20 0.36
S1PR3 Q99500 2/20 0.36
FFAR1 O14842 1/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340289 0.93 CNR2 (0.38) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL3340546 0.93 S1PR1 (0.41) S1PR1NPC1NFKB1RAB9ANFKB2
SCHEMBL3346890 0.92 SMN1; SMN2 (0.44) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL13330594 0.87 S1PR1 (0.38) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL3340910 0.87 S1PR1 (0.36) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL3340664 0.86 S1PR1 (0.36) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL2503216 0.85 SMN1; SMN2 (0.43) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL2500341 0.85 NPC1 (0.44) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL3342980 0.85 S1PR1 (0.42) CNR2S1PR1NPC1NFKB1RAB9A
SCHEMBL3340987 0.83 NPC1 (0.39) CNR2S1PR1NPC1NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 CNR2 35/4885S1PR1 1/4885NPC1 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.